Generic Recarbrio Availability
Last updated on Nov 6, 2024.
Recarbrio is a brand name of cilastatin/imipenem/relebactam, approved by the FDA in the following formulation(s):
RECARBRIO (cilastatin sodium; imipenem; relebactam - powder;intravenous)
-
Manufacturer: MSD MERCK CO
Approval date: July 16, 2019
Strength(s): EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL [RLD]
Has a generic version of Recarbrio been approved?
No. There is currently no therapeutically equivalent version of Recarbrio available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Recarbrio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
β-lactamase inhibitors
Patent 8,487,093
Issued: July 16, 2013
Inventor(s): Blizzard Timothy A. & Chen Helen & Gude Candido & Hermes Jeffrey D. & Imbriglio Jason & Kim Seongkon & Wu Jane Y. & Mortko Christopher J. & Mangion Ian & Rivera Nelo & Ruck Rebecca T. & Shevlin Michael
Assignee(s): Merck Sharp & Dohme Corp.Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.
Patent expiration dates:
- March 21, 2033✓✓✓
- March 21, 2033✓✓✓
- March 21, 2033✓✓✓
- March 21, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 16, 2024 - NEW CHEMICAL ENTITY
- July 16, 2029 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Recarbrio (cilastatin / imipenem / relebactam)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: carbapenems/beta-lactamase inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.